ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency.
Animals
Disease Resistance
/ genetics
Disease Susceptibility
/ immunology
Epithelium
/ immunology
Genetic Predisposition to Disease
Genotype
Germinal Center
/ immunology
Host-Pathogen Interactions
/ genetics
Humans
Inducible T-Cell Co-Stimulator Ligand
/ genetics
Infections
/ etiology
Mutation
Organ Specificity
Journal
Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
06
01
2021
revised:
28
02
2021
accepted:
01
03
2021
pubmed:
24
3
2021
medline:
11
3
2022
entrez:
23
3
2021
Statut:
ppublish
Résumé
Autosomal recessive mutations in Inducible T Cell Costimulator Ligand (ICOSLG) result in a combined immunodeficiency syndrome of humans, saliently marked by recurrent respiratory tract infections and significant disease with DNA-based viruses at epithelial barriers, including human papillomavirus (HPV). These features are also seen in persons with loss of function of the complementary gene, ICOS. The infection phenotypes associated with these natural experiments disclose a critical role of the corresponding proteins, ICOSL and ICOS, in human immunity at mucocutaneous barriers. Here, we review the syndromes of ICOSL and ICOS deficiency and explore the mechanisms by which the ICOSL:ICOS axis mediates epithelial host defenses.
Identifiants
pubmed: 33756276
pii: S0952-7915(21)00021-2
doi: 10.1016/j.coi.2021.03.001
pii:
doi:
Substances chimiques
ICOSLG protein, human
0
Inducible T-Cell Co-Stimulator Ligand
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-26Subventions
Organisme : CIHR
ID : 201809PJT-407084-IT-CFAC-163753
Pays : Canada
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.